Therapeutic Targets for Neuroprotection in Acute Ischemic Stroke: Lost in Translation?

Jeannette N. Stankowski^{1,2} and Rishi Gupta^{3-5,*}

Abstract

The development of a suitable neuroprotective agent to treat ischemic stroke has failed when transitioned to the clinical setting. An understanding of the molecular mechanisms involved in neuronal injury during ischemic stroke is important, but must be placed in the clinical context. Current therapeutic targets have focused on the preservation of the ischemic penumbra in the hope of improving clinical outcomes. Unfortunately, most patients in the ultra-early time windows harbor penumbra but have tremendous variability in the size of the core infarct, the ultimate predictor of prognosis. Understanding this variability may allow for proper patient selection that may better correlate to bench models. Reperfusion therapies are rapidly evolving and have been shown to improve clinical outcomes. The use of neuroprotective agents to prolong time windows prior to reperfusion or to prevent reperfusion injury may present future therapeutic targets for the treatment of ischemic stroke. We review the molecular pathways and the clinical context from which future targets may be identified. *Antioxid. Redox Signal.* 14, 1841–1851.

STROKE REMAINS THE MOST SERIOUS AND DEBILITATING neurological disorder in the United States, making it the third leading cause of death in this country after cancer and heart disease (42). Moreover, stroke is the leading cause of serious, long-term adult disability, accounting for \$68.9 billion in health care costs and loss of economic efficiency in 2009 alone (42). The most recent statistical update by the American Heart Association Statistics Committee and Stroke Statistics Subcommittee states that approximately 795,000 people in the US experience a new or recurrent stroke, of which 610,000 cases are first attacks and the remaining 185,000 cases are recurrent in nature (42). Statistical analyses demonstrate that 87% of all strokes are ischemic in nature (42), indicating that the presence of a thrombosis, an embolism, or a systemic hypoperfusion can all lead to the obstruction of blood flow to the brain, thereby decreasing the amounts of oxygen and glucose reaching this organ (17). Research aimed at understanding and identifying molecular pathways involved in neuronal death following ischemic stroke has uncovered a myriad of cellular processes that lead to neuronal death, rendering it a highly heterogeneous neurological disorder. Processes leading to neuronal death include, amongst others, ionic imbalance, peri-infarct depolarization, glutamate-mediated excitotoxicity, oxidative stress, and apoptosis (17, 48, 51) (Fig. 1).

Despite our wealth of knowledge regarding the cellular and molecular processes underlying neuronal death following ischemic stroke, we have yet failed to develop a safe and effective neurotherapeutic that can prevent stroke-induced cell death. The only pharmacological agent that has been approved by the Food and Drug Administration for use in acute ischemic stroke is the thrombolytic tissue-plasminogen activator (t-PA), which, if administered intravenously within the first 3 hours of stroke onset, can improve clinical outcome 3 months after treatment (40, 44). More recently, the time window has been expanded to 4.5 hours with intravenous t-PA (30). This strategy is aimed toward clot lysis and ultimately reperfusion of the tissue downstream of the occluded cerebral artery. In spite of the benefits of t-PA, studies have shown that the administration of this thrombolytic agent is associated with a 6% risk of intracranial hemorrhage. Notably, less than 2% of patients in the community receive thrombolysis as they do not arrive at hospitals within the therapeutic window. Exogenously applied t-PA can cross the blood–brain barrier and ultimately reach and destroy the brain parenchyma via its activity as a serine protease (40, 44). More recently, it has become evident that the administration of t-PA may also enhance neurodegeneration due to t-PA's ability to interact with the NR1 subunit of *N*-methyl-D-aspartate

¹Neuroscience Graduate Program, ²Vanderbilt Kennedy Center for Research on Human Development, and Departments of ³Neurology, ⁴Neurosurgery and ⁵Radiology, Vanderbilt University, Nashville, Tennessee.

*Current affiliation: Departments of Neurology, Neurosurgery, and Radiology, Emory University School of Medicine, Atlanta, Georgia.

FIG. 1. Approximate timeline of molecular pathway onsets following ischemic stroke. Obstruction of blood flow to the brain via the presence of a thrombosis, embolism, or systemic hypoperfusion results in ischemic stroke. The subsequent lack of oxygen and glucose results in the initiation of the depicted ischemic cascade that ultimately results in neuronal death. (To see this illustration in color the reader is referred to the web version of this article at www.liebertonline.com/ars).

FIG. 2. Example of clinical progression of ischemic stroke in the setting of a large artery occlusion. A 50-year-old patient presents at 15 h from symptom onset with a left-sided weakness and was found to have (A) occlusion of the right internal carotid artery (*black arrow*) on CT angiography. A CT perfusion was performed to estimate penumbra and showed (B) reduction of the cerebral blood flow to the right middle cerebral artery territory, and (C) prolongation of the mean transit time to the right hemisphere. MRI of the brain was performed to determine the core infarct size; in (D) and (E) the diffusion weighted sequence reveals a small core (*white arrows*) relative to the perfusion defect noted on CT perfusion imaging. The patient was admitted to the neuro intensive care unit and his blood pressure was raised with vasopressor agents to attempt to maintain perfusion to the right hemisphere. At 24 h from symptom onset, his weakness worsened and a repeat MRI of the brain revealed (F) and (G) extension of the infarct on diffusion weighted sequences (*white arrows*). (To see this illustration in color the reader is referred to the web version of this article at www.liebertonline.com/ars).

(NMDA) glutamate receptors, thereby promoting calcium influx which can subsequently reach neurotoxic levels (18, 40, 44). Results such as these underline the difficulties and challenges researchers and clinicians are confronted with in the quest of developing effective and safe therapeutics for the treatment of ischemic stroke.

Despite the challenges surrounding t-PA, a recent meta-analysis of clinical trials showed that successful vessel recanalization is the most robust predictor of improved clinical outcomes (54). Due to the challenges of treating patients in a timely manner, an extension of the therapeutic window is necessary to allow for broader appeal to clinicians treating ischemic stroke victims. Advances in radiographic imaging has allowed for a potential opportunity to treat patients based on physiology as opposed to rigid time windows (Figs. 2 and 3). The time concept has been recently challenged by clinical researchers as patients have different cerebral collaterals via the Circle of Willis (21). Quantification of cerebral blood flow (CBF) can be performed using positron emission tomography (PET) imaging. Based on PET quantification methods, the core infarct, which is the territory that is irreversibly injured and can no longer be salvaged, is defined as a CBF of less than 12 cc/100 g/min. The penumbra is tissue that is structurally intact but functionally impaired due to the reduction of blood flow. This is defined as a CBF of 12–20 cc/100 g/min (2). Mismatch defined as a larger penumbra compared to the core has been the focus of clinical research in reperfusion therapy (1, 15) and may be a potential marker of determining patients suited for neuroprotection. Unfortunately, PET imaging is not

readily available in the clinical setting and thus is not a practical tool for stroke patients. Xenon CT imaging is the only technology available that can quantify CBF in a clinical setting. CT and MRI perfusion are qualitative estimates and cannot precisely define the penumbra, but can broadly define populations with mismatch (37). Although MRI and CT are not precise tools to quantify penumbra, thresholds are being developed to better identify patients with more potential for tissue salvage during reperfusion treatments and this may be beneficial to future neuroprotection trials.

Patients presenting with a cerebral artery occlusion comprise 70% of ischemic stroke patients. Mismatch is present on CT and MRI in up to 45% of patients at 24 hours from symptom onset (35). A recent meta-analysis (49) of patients treated with thrombolytics in the presence of mismatch was found to have a higher rate of reperfusion, but also higher rates of mortality. The penumbra appears to be consistently present, but it is the size of the core prior to reperfusion treatment that seems to predict hemorrhagic complications (6, 29) and clinical outcomes (34). Thus, clinical trial designs based on rigid time windows or on pre-determined mismatch percentages may poorly select the patients most likely to benefit from neuroprotective therapeutics and moreover test the pathophysiology of the therapy being given. Identifying the core infarct threshold destined to a poor clinical outcome is crucial in determining the patients most likely to profit from reperfusion and neuroprotection trials.

While the use of t-PA is aimed at re-establishing circulation to an ischemic area, a myriad of studies have been conducted with

FIG. 3. Example of reperfusion therapy beyond traditional time window. A 75-year-old patient presented with left sided weakness 3 days earlier and was noted to have (A) and (B) a small diffusion weighted core (*white arrows*) infarct on MRI. (C) CT perfusion imaging showed prolongation of the mean transit time to the right hemisphere and provided an estimate of penumbra. (D) A cerebral angiogram revealed the presence of a right middle cerebral artery occlusion (*black arrow*) that was the culprit for the mismatch. (E) A stent was successfully implanted (*dashed black arrow*) and revealed marked improvement in the (F) mean transit time to the right hemisphere. The patient had marked improvement in his weakness and returned to near baseline function at 30 day follow up. (To see this illustration in color the reader is referred to the web version of this article at www.liebertonline.com/ars).

the goal to identify neuroprotective agents that can halt neuronal death in ischemic stroke. Despite the fact that many of these neuroprotective agents were successful in preclinical stroke models involving cell lines and animal models, not a single one has proven to be advantageous for clinical outcome in patients who suffered from ischemic stroke (18). Lack of success may be explained by the fact that many preclinical trials focus on the role of only one molecular pathway involved in cell fate following ischemic stroke, as opposed to the myriad of events elicited in this heterogeneous disease (Fig. 1). Moreover, there is a lack of model systems aside from rodents, and within rodent systems themselves, there is a deficiency in data from aging and diseased animals (56). Data evaluating long-term neurological outcomes as well as the lasting benefits of given treatments following ischemic stroke are also absent from current stroke models (56). Another concern is the insufficient collection of data on the pharmacokinetics of various drugs in preclinical settings involving rodent models, which may account for why failures of these drugs have been observed in human clinical trials (10, 56). Notably, although the use of cell culture models has allowed scientists to identify and understand complex cellular and molecular pathways involved in ischemic stroke and reperfusion (Figs. 1 and 4), they do not represent the intricate physiology of the human brain, thereby posing yet another challenge for the translation of basic science work to the clinical setting (56).

For the proper development of effective and safe neuroprotective agents, it is of utmost importance to understand the

molecular processes activated upon ischemic stroke (Fig. 1), as well as the appropriate clinical settings to which they may apply. Given the heterogeneity of this neurological disorder, it is currently speculated that a successful neurotherapeutic will not only target one molecular mechanism, but instead several of these highly complex pathways at once. Additionally, it is important to understand that neuroprotection may delay the process of neuronal death, but without definitive reperfusion therapy the tissue will continue to undergo infarction.

During ischemic stroke, the obstruction of CBF to the brain results in a drastic decrease in glucose and oxygen levels to the affected brain region. Prototypic brain damage following ischemic stroke is characterized by two main areas: the inner core and the surrounding penumbra. The core is a brain region of maximum and irreversible damage, where ATP levels are completely depleted and neurons undergo necrotic cell death (48). In contrast, neurons located in the surrounding ischemic penumbra are functionally impaired, unlike those of the ischemic core, and are potentially salvageable if appropriate neurotherapeutics are administered during the therapeutic window of opportunity, which is the critical time period during which the brain surrounding the core is at risk. Within the ischemic penumbra, ATP levels are decreased, but not fully depleted, and neurons within this region are prone to undergo apoptosis (46). Consequently, the penumbra is considered to be an essential target for therapeutic intervention with the ultimate goal of improving functional outcome and

FIG. 4. Approximate timeline of molecular pathway onsets following reperfusion. The restoration of blood flow to the brain after ischemic stroke allows the reestablishment of glucose and oxygen supply to the damaged area. Despite the benefits of restoring blood flow to the brain, reperfusion injury has become an intensive area of study, as this process results in the activation of many molecular pathways that enhance neuronal death. The approximate timing of these events is shown above. (To see this illustration in color the reader is referred to the web version of this article at www.liebertonline.com/ars).

recovery following ischemic stroke (48, 51). As discussed earlier, this target must be considered in the context of the size of the core infarct prior to initiation of treatment, as the extent of the core correlates to clinical outcomes.

Under normoxic conditions, the main function of the neuron is to conduct electrical impulses in form of action potentials. In order to process and transmit these impulses successfully, ions such Na^+ , K^+ , and Ca^{2+} have to be maintained at different concentrations across the neuronal plasma membrane. As a result, 50%–60% of the total ATP synthesized in the brain is used for the activity of energy-dependent ionic pumps that are responsible for the maintenance of these electrochemical concentration gradients (19). In the case of ischemic stroke, obstruction of CBF to the brain, and subsequent lack of oxygen and glucose supply to the brain, results in a drastic reduction in ATP production via oxidative phosphorylation in the mitochondria, which consequently leads to decreased total ATP levels within 2 minutes following the insult (17, 19, 51). This lack of ATP affects the ability of the ATP-dependent ionic pumps to function properly, resulting in the inability of neurons to maintain their ionic homeostasis (16). The subsequent cytosolic increase in Na^+ and decrease in K^+ concentrations leads to the depolarization of neuronal membranes (51). In the ischemic core, this sudden and profound loss of membrane potential is termed anoxic depolarization (AD), an event which is characterized by the death of neurons in this brain region along with the opening of voltage gated Ca^{2+} channels, allowing rapid influx of Ca^{2+} into neurons (32, 33, 48, 51). Moreover, the core propagates spontaneous electrical waves known as peri-infarct depolarizations (PID) to the ischemic penumbra, leading to rapid de- and repolarizations of these neurons (20, 48, 51). Studies have demonstrated a direct correlation between the number of PIDs and the extent of infarction in brain regions adjacent to the ischemic core (33, 48). While AD occurs within minutes following the initial insult, recurring PIDs have been shown to arise in the brain region surrounding the ischemic core within the first 3–4 hours following stroke (33, 51). Given the rapidity of ADs, the ischemic core is beyond therapeutic reach. However, the ischemic penumbra serves as a potential target for therapeutic intervention with the goal of reducing the frequency of PIDs in this area, thereby decreasing the number of “at-risk” neurons and preventing a further expansion of the ischemic core into the surrounding tissue (32, 48). Studies have demonstrated that therapeutic agents that block Na^+ channels counteract the primary events in stroke. Drugs such as lidocaine, tetrodotoxin, lamotrigine, BW-1003C87, and BW-619C89 have all been shown to provide protection against ischemic stroke via their ability to decrease the rate of ATP depletion and to reduce the ischemia-induced release of glutamate in animal models of stroke (12, 22, 26, 38, 46, 58). Unfortunately, none of these drugs have shown to be beneficial for clinical outcome in human stroke (51). Given the failure of the use of Na^+ channel blockers as a means of therapeutic intervention, Chen *et al.* investigated the potential of hypothermia as a therapeutic target. Using animal models to study acute ischemic stroke, they demonstrate that the number of depolarizations as well as the extent and size of infarction significantly decreased in animals that were kept at hypothermic temperatures (30°C) (11). As a result, the use of hypothermia could prove to be a suitable intervention for the treatment of ischemic stroke and the improvement of clinical outcome.

The loss of ATP and the resulting inability of molecular pumps to maintain ionic gradients across the neuronal membrane ultimately results in the depolarization of neurons, an event that is accompanied by the influx of Ca^{2+} into neurons via voltage-gated Ca^{2+} channels (48). The presence of Ca^{2+} in synaptic boutons triggers the release of neurotransmitters into the synaptic cleft. The neurotransmitter of particular interest for the pathology associated with ischemic stroke is the major excitatory neurotransmitter glutamate. Under physiological conditions, cytosolic glutamate concentrations are approximately 10 mM, while synaptic glutamate concentrations are in the micromolar range (17, 48). The main task of this excitatory neurotransmitter is the initiation of action potentials in the postsynaptic neuron, an event that is governed via the interaction of glutamate with ionotropic and metabotropic glutamate receptors. The presence of sodium-dependent glutamate transporters in pre- and postsynaptic membranes assures the maintenance of appropriate glutamate gradients across the plasma membrane as well as proper clearing of glutamate from the synaptic cleft and is thereby directly involved in the regulation of cellular signaling (17, 29).

The rise in cytosolic Na^+ concentrations following ischemic stroke results in the reversal of glutamate transporters, allowing glutamate to flow from the cytosol into the synaptic cleft down its concentration gradient (17). Given the lack of evidence for extracellular metabolism of glutamate, the reversal of the activity of the glutamate transporters prevents the reuptake of glutamate into the cell, thereby allowing extracellular glutamate concentrations to reach neurotoxic levels (55). Specifically, studies have shown that extracellular glutamate levels can rise up to 80 μM and remain at these highly neurotoxic concentrations for several hours (51). The subsequent effect of the presence of high levels of glutamate within the synaptic cleft is the activation of *N*-methyl-D-aspartate (NMDA) as well as α -amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid (AMPA) receptors, both of which belong to the ionotropic glutamate receptor family (17, 51). Given that NMDA receptors are the prominent route of Ca^{2+} influx during glutamatergic transmission, their opening results in a drastic increase in cytosolic Ca^{2+} levels (48). While Ca^{2+} is involved in the regulation of a variety of cellular processes including cell growth, differentiation, and enzyme function, high cytosolic Ca^{2+} levels also promote the activation of cellular cascades, leading to cell death (48, 51). In cell culture and animal models of stroke, modifications of glutamatergic signaling via the use of NMDA antagonists as well as the blockage of presynaptic glutamate release have been found to be neuroprotective; however, these results failed to translate to the clinical setting (24, 48, 51).

In contrast to NMDA receptors, AMPA receptors are impermeable to Ca^{2+} by virtue of their GluR2 subunit. Interestingly, by using the oxygen–glucose deprivation (OGD) paradigm as an *in vitro* model to study brain ischemia, several studies have shown that both mRNA and protein levels of the GluR2 subunit are substantially reduced following ischemia (25, 41, 50, 52). Moreover, Liu and colleagues demonstrate that neuronal exposure to OGD promotes the internalization of GluR2 containing AMPA receptors, while promoting the insertion of AMPA receptors lacking the GluR2 subunit into the postsynaptic membrane (41). This change in subunit composition of AMPA receptors renders these receptors permeable to Ca^{2+} , thereby further increasing Ca^{2+} influx. The

final outcome of this subunit change is the initiation of delayed neuronal cell death mediated by AMPA receptors (17, 41), suggesting that AMPA receptors which lack GluR2 subunits present another suitable target for the development of neurotherapeutics.

While NMDA and AMPA receptors can directly influence Ca^{2+} influx into neurons, metabotropic glutamate receptors (mGluRs) have been shown to indirectly govern Ca^{2+} influx (7). Metabotropic glutamate receptors belong to the family of G-protein coupled receptors, indicating that the binding of glutamate to these receptors results in the initiation of various downstream signaling cascades (7). Nevertheless, it has been shown that metabotropic glutamate receptors can also contribute to excitotoxicity, specifically via the activity of mGluRs belonging to group 1 of the metabotropic glutamate receptor family, including mGluR1 and mGluR5. These receptors are predominantly located at the postsynaptic membrane, and it has been shown that mGluR5 is functionally and physically associated with NMDA receptors, thereby enhancing Ca^{2+} influx into neurons (7, 17). As a result, decreasing excitotoxicity via the use of mGluR5 antagonist may present another potential target for the development of neurotherapeutics (17, 52).

Recent studies have demonstrated a link between excess intracellular Ca^{2+} levels and the activation of neuronal nitric oxide synthase (nNOS), resulting in increased levels of intracellular nitric oxide (NO), which, due to its unpaired electron, is con-

sidered a free radical and can therefore 'steal' electrons from other molecules (24, 48). NO enhances the formation of reactive oxygen species (ROS), including superoxide ($\text{O}_2^{\cdot-}$), hydroxyl radicals ($\text{OH}^{\cdot}$), and peroxynitrites (ONOO^-), all of which can ultimately damage major cellular macromolecules, such as nucleic acids, proteins, and lipids (24). Given the high lipid content of the brain, this organ is particularly susceptible to attack by ROS. Lipid peroxidation has been shown to result in the formation of a variety of by-products, including toxic aldehydes such as 4-hydroxy-2-nonenal (4-HNE) and isoprostanes that can subsequently damage other cellular components (48).

Under physiological conditions, cells are equipped with antioxidants that act as a cellular defense mechanism to aid in the scavenging and removal of ROS, thereby decreasing the damaging effects of ROS on cellular integrity. Antioxidants, including the main intracellular low molecular weight antioxidant glutathione, as well as catalase and superoxide dismutase, aid in the cellular detoxification of ROS (48). During ischemic stroke, however, the balance between ROS and antioxidants becomes disturbed due to the rapid and excessive generation of ROS and the inability of antioxidants to reduce these levels. This imbalance is collectively referred to as oxidative stress, and it has been identified as a common theme in a myriad of acute and chronic neurological diseases (14, 17, 24, 48, 51). Given the damaging effects of ROS on cellular

FIG. 5. Clinical example of reperfusion injury in the setting of reperfusion therapy. A 65-year-old woman presented with recurring episodes of right sided weakness and speech difficulties. (A) A CT perfusion image showed a large area of reduced perfusion to the left hemisphere (*white arrow*). (B) Cerebral angiography was performed and showed a severe stenosis of the left internal carotid artery (*black arrow*). (C) A carotid stent (*dashed black arrow*) was placed to revascularize the severe narrowing but was complicated with (D) an embolus to the left middle cerebral artery (*black arrow*). (E) A stent was implanted in the left middle cerebral artery (*dashed black arrow*) with successful reperfusion achieved at 60 min from the initial time of the embolus. (F) A large hemorrhage (*dashed white arrow*) was noted within a sizeable infarct despite rapid reperfusion of the iatrogenic embolus. The mechanism was likely reperfusion injury. (To see this illustration in color the reader is referred to the web version of this article at www.liebertonline.com/ars).

integrity and survival, the removal of ROS by increasing antioxidant levels has been a focus of interest and may present a suitable target for the development of neurotherapeutics (24, 48, 51). While the addition or overexpression of antioxidants has been shown to result in neuroprotection *in vitro*, the use of antioxidants in human stroke has not provided the same positive results (51). For instance, the use of Bilobalide (EGB 761), an extract from *Ginkgo biloba* leaves, is neuroprotective in transient ischemia, yet its use in stroke is not recommended due to increases in intracerebral hemorrhage (51). Studies using the NOS inhibitor Lubeluzole have shown to be ineffective in stroke (16), while recent studies using BN 80933, an agent that affects both nNOS and lipid peroxidation, have shown more promising results (8). Given that ROS are generated under physiological conditions, such as during oxidative phosphorylation in mitochondria or as by-products of enzyme activities such as tyrosine hydroxylase and monoamine oxidase (24, 48), the development of a safe and effective therapeutic targeted at the reduction of ROS poses another challenge for researchers and clinicians.

In order to identify an effective therapeutic agent for ischemic stroke, a precise understanding of the cell death pathways associated with this neurological disorder is required. As a result, an area of intense research has been devoted to cell death pathways activated during ischemic stroke. Due to the rapid loss of ATP in the ischemic core, neurons in this brain region undergo necrosis. In contrast, low levels of ATP present in the ischemic penumbra activate cell death pathways that ultimately lead to programmed cell death (apoptosis) (17, 48). While neurons in the ischemic core are beyond therapeutic reach, research has predominantly focused on identifying agents that can block neuronal death in the ischemic penumbra by interfering with a variety of molecular players involved in apoptosis, including cytochrome *c*, Bcl-2-related proteins, and caspases (17, 48, 51).

During the first few hours after ischemic stroke, a range of signals such as ionic imbalance, ROS generation, DNA damage, caspase activation, and mitochondrial swelling can trigger apoptosis in the ischemic penumbra, rendering these initial hours a suitable opportunity for intervention (17, 48). From a biochemical perspective, apoptosis is primarily characterized by the activation of cysteine proteases, known as caspases, which cleave substrates specifically after aspartate residues. One way caspases can be activated following ischemic stroke is via the release of cytochrome *c* from mitochondria in response to ionic imbalance and mitochondrial swelling. Once in the cytosol, cytochrome *c* associates with Apaf-1 and procaspase-9 to form a structure known as the apoptosome (4). The apoptosome then cleaves and activates executioner caspases, such as caspase-3, -6, and -7. Executioner caspases then continue to cleave their substrates including iCAD, PARP, actin, and p75, resulting in the characteristic morphological changes observed in apoptosis, including membrane blebbing, DNA condensation, and nuclear fragmentation, as well as the redistribution of phosphatidylserine residues to the outer plasma membrane that ultimately prevent the leakage of potentially harmful cellular contents into the surrounding tissue (3, 4, 48). Research in the field of programmed cell death has identified several signaling pathways that can result in cell death, including the extrinsic and intrinsic pathways of apoptosis, death receptor mediated apoptosis, and caspase-independent apoptotic cell

death. While a detailed analysis of all pathways is beyond the scope of this article, it is important to know that research aimed at the identification of effective neurotherapeutics has targeted a variety of molecules involved in apoptosis, including caspases, Bcl-2 family members, and poly(ADP-ribose) polymerase (PARP) (48).

Several studies have shown that the administration of caspase inhibitors can reduce infarct volumes in models of stroke (43, 51, 53). Zhao *et al.* demonstrate that the overexpression of the Bcl-2 protein protects against apoptotic cell death, resulting in increased neuronal survival following the ischemic insult (65). Given that one of the characteristic morphological changes seen in apoptosis is DNA fragmentation, several groups have investigated the effect of inhibiting PARP following ischemic stroke (64, 66). While PARP is involved in mediating poly(ADP-ribosylation) under physiological conditions, ensuring the maintenance of genomic integrity, research has shown that under conditions of cell stress, poly(ADP-ribosylation) actually governs mitochondrial failure and promotes cell death (64,66). Studies investigating the effect of PARP on neuronal death following ischemic stroke demonstrate that the inhibition of PARP activity reduces neuronal death by preventing the translocation of apoptosis inducing factor (AIF) from the mitochondria into the nucleus (64, 66).

Another area of intense research in the field of ischemic stroke is reperfusion injury, which may occur in patients following successful restoration of blood flow to an ischemic brain region (59) (Fig. 5). Although rapid reperfusion of an ischemic brain region is of utmost importance in order to salvage brain tissue, this process also harbors a variety of dangers that can worsen outcome if complications occur. While the initial ischemic stroke leads to the activation of a myriad of cellular and molecular cascades that ultimately result in neuronal death (Fig. 1) (31, 48, 51), reperfusion of the damaged brain area adds to the degree of brain injury due to the activation of additional signaling pathways (Fig. 4). Given that a detailed analysis of all pathways implicated in reperfusion injury is beyond the scope of this review, a focus on oxidative stress, a major and early event elicited following reperfusion injury, is presented here (31, 63).

Oxidative stress is characterized by a rapid and excessive increase in ROS and a decrease in the detoxifying activities of intracellular antioxidants (31, 48, 63). While ischemia results in the accumulation of free fatty acids, and specifically arachidonic acid, through the breakdown of lipid membranes, reperfusion leads to the generation of ROS via the metabolism of these same fatty acids (60). Specifically, arachidonic acid is metabolized via both the lipoxygenase and cyclooxygenase pathways leading to the generation of prostaglandins and superoxides (60). At this point, an imbalance exists between pro- and antioxidants, posing the brain at a higher risk for subsequent damage. ROS produced during dysregulated antioxidant homeostasis not only injure other cellular macromolecules, thereby enhancing neuronal death, but also activate molecular signaling cascades leading to the recruitment of inflammatory cells to the site of injury (31, 48). As a result, identifying treatments that can scavenge ROS, and thereby decrease the deleterious effects of ROS on other macromolecular structures, would present a potential avenue for the development of safe and effective neurotherapeutics that can decrease neuronal death following reperfusion injury.

TABLE 1. METHODS USED TO REDUCE REPERFUSION INJURY

<i>Agent/Methodology</i>	<i>Proposed Mechanism</i>	<i>Clinical Application and Outcome</i>	<i>References</i>
Cooling for Acute Ischemic Brain Damage (COOL AID); ICTuS Trial	Suppression of generation of reactive oxygen species and inflammatory responses.	Used in clinical settings. Decreased brain damage following ischemia and reperfusion.	13, 28, 36, 47
Hyperbaric oxygen preconditioning (HBO)	Increased antioxidant activity of catalase and superoxide dismutase results in decreased ischemia-reperfusion injury.	Not used in clinical settings.	39, 57
Normobaric oxygen therapy (NBO)	NBO results in increased brain oxygen levels, decreased peri-infarct depolarizations, improved brain lactate levels and favorably altered cerebral blood volumes.	Not used in clinical settings.	23, 57
Ethanol preconditioning (EtOH-PC)	Moderate ethanol ingestion causes mild oxidative stress resulting in decreased posts ischemic behavioral deficits, oxidative DNA damage, neuronal and dendrite degeneration as well as glia activation in the hippocampus.	Not used in clinical settings.	61
Caffeine and ethanol (Caffeinol) + hypothermia	Acting as an adenosine receptor antagonist, caffeine increases neural activity, cerebral metabolic rate and stimulates adrenaline release. An increased metabolic rate may promote the continuous functioning of metabolic pathways despite decreased reperfusion. Ethanol acts on GABA _A receptors, leading to the inhibition on NMDA receptors, thereby having antiexcitotoxic properties.	Used in clinical settings in combination with hypothermia and t-PA to reduce ischemic brain damage.	13, 66
Exercise preconditioning	Reduced expression levels of matrix metalloproteinase-9 (MMP-9) after physical exercise decreases neuronal apoptosis.	Not used in clinical settings.	9

Given the heterogeneity of ischemic stroke, one can assume that a successful neurotherapeutic will be able to interfere with several cellular and molecular processes triggered as a result of ischemic stroke at once. Identifying a therapeutic agent, or combination of therapeutic agents, that can block neuronal death while preventing devastating side effects, including excitotoxicity and cerebral hemorrhages proves to be a challenge for researchers and clinicians studying ischemic stroke.

Future Directions

Understanding the clinical context in which these neuroprotective strategies may be incorporated is essential as previously tested agents may have clinical impact if tested in the appropriate set of patients. A neuroprotective agent that impacts multiple molecular pathways administered early in the clinical course in a patient with a small core infarct and a large area of penumbra may be the ideal target. This strategy may afford a delay in the transition of penumbra to core while definitive reperfusion strategies are considered. The combination or multimodal approach may allow for treatment of a larger proportion of patients by extending the time window. A second use of neuroprotection may be to deliver the agent in the hopes of preventing reperfusion hemorrhage (Table 1). Successful reperfusion strategies are hampered by hemorrhagic complications that are partially due to reperfusion injury (Figs. 4 and 5). Removal of hemorrhagic risks may help to benefit a larger population with reperfusion techniques. Treatment paradigms surrounding reperfusion will likely provide the best therapeutic targets going forward.

Acknowledgments

The authors wish to thank Dr. BethAnn McLaughlin for the invitation to contribute to the Stroke Forum of *Antioxidants & Redox Signaling*, as well as the members of the McLaughlin lab for helpful suggestions and discussion. This work was supported by the Vanderbilt Neuroscience predoctoral training Fellowship T32 MH064913 (JS).

References

- Albers GW, Thijs VN, Wechsler L, Kemp S, Schlaug G, Skalabrin E, Bammer R, Kakuda W, Lansberg MG, Shuaib A, Coplin W, Hamilton S, Moseley M, and Marks MP. DEFUSE Investigators. *Ann Neurol* 60: 508–517, 2006.
- Baron JC. Perfusion thresholds in human cerebral ischemia: Historical perspective and therapeutic implications. *Cerebrovasc Dis* 11: 2–08, 2001.
- Beere H and Green DR. Stress management-heat shock protein-70 and the regulation of apoptosis. *Trends Cell Biol* 11: 6–10, 2001.
- Beere H. The stress of dying: The role of heat shock proteins in the regulation of apoptosis. *J Cell Sci* 117: 2641–2651, 2004.
- Beere HM. Death versus survival: Functional interaction between apoptotic and stress-inducible heat shock protein pathways. *J Clin Invest* 115: 2633–2639, 2005.
- Bhatt A, Vora NA, Thomas AJ, Majid A, Kassab M, Hammer MD, Uchino K, Wechsler L, Jovin TG, and Gupta R. Lower pretreatment cerebral blood volume affects hemorrhagic risks after intra-arterial revascularization in acute stroke. *Neurosurgery* 63: 874–878, 2008.
- Bruno V, Battaglia G, Copani A, D'Onofrio A, Di Iorio P, De Blasi A, Melchiorri D, Flor PJ, and Nicoletti F. Metabotropic glutamate receptor subtypes as targets for neuroprotective drugs. *J Cereb Blood Flow Metab* 21: 1013–1033, 2001.
- Chabrier PE, Auguet M, Spinnewyn B, Auvin S, Cornet S, Demerle-Pallardy C, Guilmard-Favre C, Marin JG, Pignol B, Gillard-Roubert V, Roussillot-Charnet C, Schulz J, Viossat I, Bigg D, and Moncada S. BN 80933, a dual inhibitor of neuronal nitric oxide synthase and lipid peroxidation: A promising neuroprotective strategy. *Proc Natl Acad Sci USA* 96: 10824–10829, 1999.
- Chaudhry K, Rogers R, Gui M, Lai Q, Goel G, Liebelt B, Ji X, Curry A, Carranza A, Jimenez DF, and Ding Y. Matrix metalloproteinase-9 (MMP-9) expression and extracellular signal-regulated kinase 1 and 2 (ERK1/2) activation in exercise-reduced neuronal apoptosis after stroke. *Neurosci Lett* 474:109–114, 2010.
- Chavez JC, Hurko O, Barone FC, and Feuerstein GZ. Pharmacologic interventions for stroke: Looking beyond the thrombolysis time window into the penumbra with biomarkers, not a stopwatch. *Stroke* 40: e558–e563, 2009.
- Chen Q, Chopp M, Bodzin G, and Chen H. Temperature modulation of cerebral depolarization during focal cerebral ischemia in rats: Correlation with ischemic injury. *J Cereb Blood Flow Metab* 13: 389–394, 1993.
- Crumrine RC, Bergstrand K, Cooper AT, Faison WL, and Cooper BR. Lamotrigine protects hippocampal CA1 neurons from ischemic damage after cardiac arrest. *Stroke* 28: 2230–2237, 1997.
- Damman P, Hirsch A, Windhausen F, Tijssen JGP, de Winter RJ, and ICTUS Investigators. 5-year clinical outcomes in the ICTUS (Invasive versus conservative treatment in unstable coronary syndromes) Trial: A randomized comparison of an early invasive versus selective invasive management in patients with non-ST-segment elevation acute coronary syndrome. *JACC* 55: 858–864, 2010.
- Danielson SR and Andersen JK. Oxidative and nitrative protein modifications in Parkinson's disease. *Free Radic Biol Med* 44: 1787–1794, 2008.
- Davis SM, Donnan GA, Parsons MW, Levi C, Butcher KS, Peeters A, Barber PA, Bladin C, De Silva DA, Byrnes G, Chalk JB, Fink JN, Kimber TE, Schultz D, Hand PJ, Frayne J, Hankey G, Muir K, Gerraty R, Tress BM, Desmond PM, and EPITHET Investigators. Effects of alteplase beyond 3 hours after stroke in the echoplanar imaging thrombolytic evaluation trial (EPITHET): A placebo-controlled randomised trial. *Lancet Neurol* 7: 299–309, 2008.
- Diener HC, Cortens M, Ford G, Grotta J, Hacke W, Kaste M, Koudstaal PJ, Wessel T, for the LUB-INT-13 Investigators. Lubeluzole in acute ischemic stroke treatment. A double-blind study with an 8-hour inclusion window comparing a 10-mg daily dose of lubeluzole with placebo. *Stroke* 31: 2543–2551, 2000.
- Doyle KP, Simon RP, and Stenzel-Poore MP. Mechanisms of ischemic brain damage. *Neuropharmacology* 55: 310–318, 2008.
- Ducruet AF, Grobelny BT, Zacharia BE, Hickman ZL, Yeh ML, and Connolly ES. Pharmacotherapy of cerebral ischemia. *Expert Opin Pharmacother* 10: 1895–1906, 2009.
- Erecinska M and Silver IA. Ions and energy in mammalian brain. *Prog Neurobiol* 43: 37–71, 1994.
- Fabrizius M, Fuhr S, Buatia R, Boutelle M, Hashemi P, Strong AJ, and Lauritzen M. Cortical spreading depression and peri-infarct depolarization in acutely injured human cerebral cortex. *Brain* 129: 778–790, 2006.

21. Fink JN, Kumar S, Horkan C, Linfante I, Selim MH, Caplan LR, and Schlaug G. The stroke patient who woke up: Clinical and radiological features, including diffusion and perfusion MRI. *Stroke* 33: 988–993, 2002.
22. Fujitani T, Adachi N, Miyazaki H, Liu K, Nakamura Y, Kataoka K, and Arai T. Lidocaine protects hippocampal neurons against ischemic damage by preventing increase of extracellular excitatory amino acids: A microdialysis study in Mongolian gerbils. *Neurosci Lett* 179: 91–93, 1994.
23. Fujiwara N, Murata Y, Arai K, Egi Y, Lu J, Wu O, Singhal AB, and Lo EH. Combination therapy with normobaric oxygen (NBO) plus thrombolysis in experimental ischemic stroke. *BMC Neurosci* 10: 79–87, 2009.
24. Gilgun-Sherki Y, Rosenbaum Z, Melamed E, and Offen D. Antioxidant therapy in acute central nervous system injury: Current state. *Pharmacol Rev* 54: 271–284, 2002.
25. Gorter JA, Petrozzino JJ, Aronica EM, Rosenbaum DM, Opitz T, Bennett MVL, Connor JA, and Zukin RS. Global ischemia induces downregulation of Glur2 mRNA and increases AMPA receptor-mediated Ca^{2+} influx in hippocampal CA1 neurons of gerbil. *J Neurosci* 17: 6179–6188, 1997.
26. Graham SH, Chen J, Lan J, Leach MJ, and Simon RP. Neuroprotective effects of a use-dependent blocker of voltage-dependent sodium channels, BW619C89 in rat middle cerebral artery occlusion. *JPET* 269: 854–859, 1994.
27. Gu Y, Shrivastava IH, Amara SG, and Bahar I. Molecular simulations elucidate the substrate translocation pathway in a glutamate transporter. *Proc Natl Acad Sci USA* 106: 2589–2594, 2009.
28. Guluma KZ, Oh H, Yu SW, Meyer BC, Rapp K, and Lyden PD. Effect of endovascular hypothermia on acute ischemic edema: Morphometric analysis of the ICTuS trial. *Neurocrit Care* 8: 42–47, 2008.
29. Gupta R, Yonas H, Gebel J, Goldstein S, Horowitz M, Grahovac SZ, Wechsler LR, Hammer MD, Uchino K, and Jovin TG. Reduced pretreatment ipsilateral middle cerebral blood flow is predictive of symptomatic hemorrhage post-intra-arterial thrombolysis in patients with middle cerebral artery occlusion. *Stroke* 37: 2526–2530, 2006.
30. Hacke W, Kaste M, Bluhmki E, Brozman M, Davalos A, Guidetti D, Larrue V, Lees KR, Medeghri Z, Machnig T, Schneider D, von Kummer R, Wahlgren N, Toni D, and ECASS Investigators. Thrombolysis with alteplase 3 to 4.5 hours after acute ischemic stroke. *N Engl J Med* 359: 1317–1329, 2008.
31. Iida H, Schmeichel AM, Wang Y, Schmelzer JD, and Low PA. Orchestration of the inflammatory response in ischemia-reperfusion injury. *J Peripher Nerv Syst* 12: 131–138, 2007.
32. Jarvis CR, Anderson TR, and Andrew D. Anoxic depolarization mediates acute damage independent of glutamate in neocortical brain slices. *Cereb Cortex* 11: 249–259, 2001.
33. Joshi I and Andrew RD. Imaging anoxic depolarization during ischemia-like conditions in the mouse hemi-brain slice. *J Neurophysiol* 85: 414–424, 2001.
34. Jovin TG, Yonas H, Gebel JM, Kanal E, Chang YF, Gahovac SZ, Goldstein S, and Wechsler LR. The cortical ischemic core and the consistently present penumbra is a determinant of clinical outcome in acute middle cerebral artery occlusion. *Stroke* 34: 2426–2433, 2003.
35. Kidwell CS, Alger JR, and Saver JL. Evolving paradigms in neuroimaging of the ischemic penumbra. *Stroke* 35: 2662–2665, 2003.
36. Krieger DW, DeGeorgia MA, Abou-Chebl A, Andrefsky JC, Sila CA, Katzan IL, Mayberg MR, and Furlan AJ. Cooling for acute ischemic brain damage (COOL AID). An open pilot study of induced hypothermia in acute ischemic stroke. *Stroke* 32: 1847–1854, 2001.
37. Latchaw RE, Yonas H, Hunter GJ, Yuh WT, Ueda T, Sorensen AG, Sunshine JL, Biller J, Wechsler L, Higashida R, et al. Guidelines and recommendations for perfusion imaging in cerebral ischemia: A scientific statement for healthcare professionals by the writing group on perfusion imaging, from the Council on Cardiovascular Radiology of the American Heart Association. *Stroke* 34: 1084–1104, 2003.
38. Lekieffe D and Meldrum BS. The pyrimidine-derivative, BW 1003C87, protects CA1 and striatal neurons following transient severe forebrain ischaemia in rats. A microdialysis and histological study. *Neuroscience* 56: 93–99, 1993.
39. Li J, Liu W, Ding S, Xu W, Guan Y, Zhang JH, and Sun X. Hyperbaric oxygen preconditioning induces tolerance against brain ischemia-reperfusion injury by upregulation of antioxidant enzymes in rats. *Brain Res* 1210: 223–229, 2008.
40. Liberatore GT, Samson A, Bladin C, Schleuning WD, and Medcalf RL. Vampire bat salivary plasminogen activator (Desmoteplase). A unique fibrinolytic enzyme that does not promote neurodegeneration. *Stroke* 34: 537–543, 2003.
41. Liu B, Liao M, Mielke JG, Ning K, Chen Y, Li L, El-Hayek YH, Gomez E, Zukin RS, Fehlings MG, and Wan Q. Ischemic insults direct glutamate receptor subunit 2-lacking AMPA receptors to synaptic sites. *J Neurosci* 26: 5309–5319, 2006.
42. Lloyd-Jones D, Adams R, Carnethon M, De Simone G, et al. Heart disease and stroke statistics-2009 update. A report from the American Heart Association Statistics Committee and Stroke Statistics Subcommittee. *Circulation* 119: e21–e181, 2009.
43. Loddick SA, MacKenzie A, and Rothwell NJ. An ICE inhibitor, z-VAD-DCB attenuates ischaemic brain damage in the rat. *Neuroreport* 7: 1465–1468, 1996.
44. Lopez-Atalaya JP, Roussel BD, Levrat D, Parcq J, Nicole O, Hommet Y, Benchenane K, Castel H, Leprince J, To Van D, Bureau R, Rault S, Vaudry H, Petersen KU, Santos JS, and Vivien D. Toward safer thrombolytic agents in stroke: Molecular requirements for NMDA receptor-mediated neurotoxicity. *J Cereb Blood Flow Metab* 28: 1212–1221, 2008.
45. Lu D, Zhang X, Han YY, Burke NA, Kochanek PM, Watkins SC, Graham SH, Carcillo JA, SzaboC, and Clark RSB. Intra-mitochondrial poly(ADP-ribosylation) contributes to NAD⁺ depletion and cell death induced by oxidative stress. *J Biol Chem* 278: 18426–18433, 2003.
46. Lysko PG, Webb CL, Yue TL, Gu JL, and Feuerstein G. Neuroprotective effects of tetrodotoxin as a Na⁺ channel modulator and glutamate release inhibitor in cultured rat cerebellar neurons and in gerbil global brain ischemia. *Stroke* 25: 2476–2482, 1994.
47. Martin-Schild S, Halleivi H, Shaltoni H, Barreto AD, Gonzales NR, Aronowski J, and Savitz S. Combined neuroprotective modalities coupled with thrombolysis in acute ischemic stroke: A pilot study of caffeine and mild hypothermia. *J Stroke Cerebrovasc Dis* 18: 85–96, 2009.
48. Mehta SL, Manhas N, and Raghavir R. Molecular targets in cerebral ischemia for developing novel therapeutics. *Brain Res Rev* 54: 34–66, 2007.
49. Mishra NK, Albers GW, Davis SM, Donnan GA, Furlan AJ, Hacke W, and Lees KR. Mismatch-based delayed thrombolysis: A meta-analysis. *Stroke* 41: e25–e33, 2010.

50. Noh KM, Yokota H, Mashiko T, Castillo PE, Zukin RS, and Bennett MVL. Blockade of calcium-permeable AMPA receptors protects hippocampal neurons against global ischemia-induced death. *Proc Natl Acad Sci USA* 102: 12230–12235, 2005.
51. Onteniente B, Rasika S, Benchoua A, and Guegan C. Molecular pathways in cerebral ischemia. Cues to novel therapeutic strategies. *Mol Neurobiol* 27: 33–72, 2003.
52. Pellegrini-Giampietro DE, Zukin RS, Bennet MV, Cho S, and Pulsinelli WA. Switch in glutamate receptor subunit gene expression in CA1 subfield of hippocampus following global ischemia in rats. *Proc Natl Acad Sci USA* 89: 10499–10503, 1992.
53. Rami A, Agarwal R, Botez G, and Winckler J. μ -Calpain activation, DNA fragmentation, and synergistic effects of caspase and calpain inhibitors in protecting hippocampal neurons from ischemic damage. *Brain Res* 866: 299–312, 2000.
54. Rha JH and Saver JL. The impact of recanalization on ischemic stroke outcome: A meta-analysis. *Stroke* 38:967–973, 2007.
55. Robinson MB. The family of sodium-dependent glutamate transporters: A focus on the GLT-1/EAAT2 subtype. *Neurochem Int* 33: 479–491, 1998.
56. Savitz SI and Fisher M. Future of neuroprotection for acute stroke: In the aftermath of the SAINT trials. *Ann Neurol* 61: 396–402, 2007.
57. Singhal AB. Oxygen therapy in stroke: Past, present and future. *Int J Stroke* 1: 191–200, 2006.
58. Smith SE and Meldrum BS. Cerebroprotective effect of latmotrigine after focal ischemia in rats. *Stroke* 26: 117–122, 1995.
59. Tapuria N, Kumar Y, Habib MM, Amara MA, Seifalian AM, and Davidson BR. Remote ischemic preconditioning: A novel protective method from ischemia reperfusion injury. A review. *J Surg Res* 150: 304–330, 2008.
60. Traystman RJ, Kirsch JR, and Koehler RC. Oxygen radical mechanisms of brain injury following ischemia and reperfusion. *J Appl Physiol* 71: 1185–1195, 1991.
61. Wang Q, Sun AY, Simonyi A, Kalogeris TJ, Miller DK, Sun GY, and Korthius RJ. Ethanol preconditioning protects against ischemia/reperfusion-induced brain damage: Role of NADPH oxidase derived ROS. *Free Radic Biol Med* 43: 1048–1060, 2007.
62. Wang Y, Dawson VL, and Dawson TM. Poly (ADP-ribose) signals to mitochondrial AIF: A key event in parthanatos. *Exp Neurol* 218: 193–202, 2009.
63. White BC, Sullivan JM, Degracia DJ, O'Neil BJ, Neumar RW, Grossman LI, Raflos JA, and Krause GS. Brain ischemia and reperfusion: Molecular mechanisms of neuronal injury. *J Neurol Sci* 179: 1–33, 2000.
64. Yu SW, Andrabi SA, Wang H, Kim NS, Poirier GG, Dawson TM, and Dawson VL. Apoptosis-inducing factors mediates poly(ADP-ribose) (PAR) polymer-induced cell death. *Proc Natl Acad Sci USA* 103:18314–18319, 2006.
65. Zhao H, Yenari MA, Cheng D, Sapolsky RM, and Steinberg GK. Bcl-2 overexpression protects against neuron loss within the ischemic margin following experimental stroke and inhibits cytochrome c translocation and caspase-3 activity. *J Neurochem* 85: 1026–1036, 2003.
66. Zhao X, Strong R, Piriya P, Palusinski R, Grotta JC, and Aronowski J. Caffeinol at the receptor level. Anti-ischemic effect of N-methyl-D-Aspartate receptor blockade is potentiated by caffeine. *Stroke* 41: 363–367, 2010.

Address correspondence to:

Dr. Rishi Gupta

Departments of Neurology, Neurosurgery, and Radiology

Emory University School of Medicine

49 Jesse Hill Jr. Drive, SE

Faculty Office Building #393

Atlanta, GA 30303

E-mail: rishi.gupta@emory.edu

Date of first submission to ARS Central, May 10, 2010; date of final revised submission, June 13, 2010; date of acceptance, July 10, 2010.

Abbreviations Used

4-HNE = 4-hydroxy-2-nonenal
 AD = anoxic depolarization
 AIF = apoptosis inducing factor
 AMPA = alpha-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid
 Apaf-1 = apoptotic protease activating factor 1
 Caffeinol = caffeine and ethanol
 CBF = cerebral blood flow
 COOL AID = cooling for Acute Ischemic Brain Damage
 eIF1 α = eukaryotic initiation factor 1 alpha
 ER = endoplasmic reticulum
 EtOH-PC = ethanol preconditioning
 GPx = glutathione peroxidase
 HBO = hyperbaric oxygen preconditioning
 HIF1 α = hypoxia-inducible factor 1
 HSP = heat shock protein
 iCAD = inhibitor of caspase-3-activated DNase
 ICTUS = Invasive versus Conservative Treatment in Unstable Coronary Syndromes
 IEG = immediate early genes
 mGluR = metabotropic glutamate receptors
 MMP-9 = matrix metalloproteinase-9
 NBO = normobaric oxygen therapy
 NMDA = N-methyl-D-aspartate
 nNOS = neuronal nitric oxide synthase
 NO $\cdot$ = nitric oxide
 O $_2^{\cdot-}$ = superoxide
 OGD = oxygen glucose deprivation
 OH $\cdot$ = hydroxyl radical
 ONOO $^-$ = peroxynitrate
 PARP = poly(ADP-ribose) polymerase
 PID = peri-infarct depolarization
 ROS = reactive oxygen species
 t-PA = tissue-plasminogen activator